Abstract
Targeted therapies were rationally designed to inhibit molecular pathways in tumor cells critically involved in growth and survival; however, many drugs used in targeted therapies may affect the immune system. In addition, selected conventional chemotherapeutic agents have also been reported to be endowed with direct or indirect effects on immunity, for instance via immunogenic death of tumors. Thus, cancer therapies may have off-target effects, some of which are directed to the immune system. Here, we will review some of these effects in specific therapeutic approaches. We will examine the modulation of the immune contexture in human sarcoma and melanoma induced by anti-angiogenic therapies and by BRAF inhibitors, respectively. We will then discuss how the anti-tumor agent trabectedin is selectively cytotoxic to cells of the monocytic-macrophage lineage and how these immune-related effects can be part of the response to treatment.
| Original language | English |
|---|---|
| Pages (from-to) | 83-89 |
| Number of pages | 7 |
| Journal | Cancer Immunology, Immunotherapy |
| Volume | 64 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Jan 1 2015 |
Fingerprint
Keywords
- Anti-angiogenic therapies
- BRAF inhibitors
- Immune responses
- NIBIT 2013
- Targeted therapies
- Tumor-associated myeloid cells
ASJC Scopus subject areas
- Cancer Research
- Oncology
- Immunology
- Immunology and Allergy
- Medicine(all)
Cite this
Modulation of the myeloid compartment of the immune system by angiogenic- and kinase inhibitor-targeted anti-cancer therapies. / Castelli, Chiara; Rivoltini, Licia; Rodolfo, Monica; Tazzari, Marcella; Belgiovine, Cristina; Allavena, Paola.
In: Cancer Immunology, Immunotherapy, Vol. 64, No. 1, 01.01.2015, p. 83-89.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Modulation of the myeloid compartment of the immune system by angiogenic- and kinase inhibitor-targeted anti-cancer therapies
AU - Castelli, Chiara
AU - Rivoltini, Licia
AU - Rodolfo, Monica
AU - Tazzari, Marcella
AU - Belgiovine, Cristina
AU - Allavena, Paola
PY - 2015/1/1
Y1 - 2015/1/1
N2 - Targeted therapies were rationally designed to inhibit molecular pathways in tumor cells critically involved in growth and survival; however, many drugs used in targeted therapies may affect the immune system. In addition, selected conventional chemotherapeutic agents have also been reported to be endowed with direct or indirect effects on immunity, for instance via immunogenic death of tumors. Thus, cancer therapies may have off-target effects, some of which are directed to the immune system. Here, we will review some of these effects in specific therapeutic approaches. We will examine the modulation of the immune contexture in human sarcoma and melanoma induced by anti-angiogenic therapies and by BRAF inhibitors, respectively. We will then discuss how the anti-tumor agent trabectedin is selectively cytotoxic to cells of the monocytic-macrophage lineage and how these immune-related effects can be part of the response to treatment.
AB - Targeted therapies were rationally designed to inhibit molecular pathways in tumor cells critically involved in growth and survival; however, many drugs used in targeted therapies may affect the immune system. In addition, selected conventional chemotherapeutic agents have also been reported to be endowed with direct or indirect effects on immunity, for instance via immunogenic death of tumors. Thus, cancer therapies may have off-target effects, some of which are directed to the immune system. Here, we will review some of these effects in specific therapeutic approaches. We will examine the modulation of the immune contexture in human sarcoma and melanoma induced by anti-angiogenic therapies and by BRAF inhibitors, respectively. We will then discuss how the anti-tumor agent trabectedin is selectively cytotoxic to cells of the monocytic-macrophage lineage and how these immune-related effects can be part of the response to treatment.
KW - Anti-angiogenic therapies
KW - BRAF inhibitors
KW - Immune responses
KW - NIBIT 2013
KW - Targeted therapies
KW - Tumor-associated myeloid cells
UR - http://www.scopus.com/inward/record.url?scp=84925024926&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84925024926&partnerID=8YFLogxK
U2 - 10.1007/s00262-014-1576-1
DO - 10.1007/s00262-014-1576-1
M3 - Article
C2 - 24993564
AN - SCOPUS:84925024926
VL - 64
SP - 83
EP - 89
JO - Cancer Immunology and Immunotherapy
JF - Cancer Immunology and Immunotherapy
SN - 0340-7004
IS - 1
ER -